329 related articles for article (PubMed ID: 30655151)
21. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
[TBL] [Abstract][Full Text] [Related]
22. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
Willemse SB; Baak LC; Kuiken SD; van der Sluys Veer A; Lettinga KD; van der Meer JT; Depla AC; Tuynman H; van Nieuwkerk CM; Schinkel CJ; Kwa D; Reesink HW; van der Valk M
J Viral Hepat; 2016 Dec; 23(12):950-954. PubMed ID: 27405785
[TBL] [Abstract][Full Text] [Related]
23. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
Elfeki MA; Abou Mrad R; Modaresi Esfeh J; Zein NN; Eghtesad B; Zervos X; Hanouneh IA; O'Shea R; Carey WD; Alkhouri N
Transplantation; 2017 May; 101(5):996-1000. PubMed ID: 27631598
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
[TBL] [Abstract][Full Text] [Related]
25. Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Chevallier E; Büchler M; Caillard S; Bouvier N; Colosio C; Rivalan J; Sayegh J; Bertrand D; Le Meur Y; Thierry A; Garrouste C; Rerolle JP; Rostaing L; Gatault P
Transplant Proc; 2020 Dec; 52(10):3179-3185. PubMed ID: 32636068
[TBL] [Abstract][Full Text] [Related]
26. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
[TBL] [Abstract][Full Text] [Related]
27. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
Abozeid M; Alsebaey A; Abdelsameea E; Othman W; Elhelbawy M; Rgab A; Elfayomy M; Abdel-Ghafar TS; Abdelkareem M; Sabry A; Fekry M; Shebl N; Rewisha E; Waked I
Int J Infect Dis; 2018 Oct; 75():109-114. PubMed ID: 30077791
[TBL] [Abstract][Full Text] [Related]
28. Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Bhamidimarri KR; Ladino M; Pedraza F; Guerra G; Mattiazzi A; Chen L; Ciancio G; Kupin W; Martin P; Burke G; Roth D
Transpl Int; 2017 Sep; 30(9):865-873. PubMed ID: 28332729
[TBL] [Abstract][Full Text] [Related]
29. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Persico M; Aglitti A; Aghemo A; Rendina M; Lleo A; Ciancio A; Di Marco V; Lampertico P; Brunetto MR; Zuin M; Andreone P; Villa E; Troshina G; Calvaruso V; Degasperi E; Coco B; Giorgini A; Conti F; Di Leo A; Marzi L; Boccaccio V; Bollani S; Maisonneuve P; Bruno S
Aliment Pharmacol Ther; 2018 Jun; 47(12):1705-1712. PubMed ID: 29722439
[TBL] [Abstract][Full Text] [Related]
30. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
31. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
[TBL] [Abstract][Full Text] [Related]
32. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Beinhardt S; Al Zoairy R; Ferenci P; Kozbial K; Freissmuth C; Stern R; Stättermayer AF; Stauber R; Strasser M; Zoller H; Watschinger B; Schmidt A; Trauner M; Hofer H; Maieron A
Transpl Int; 2016 Sep; 29(9):999-1007. PubMed ID: 27203857
[TBL] [Abstract][Full Text] [Related]
33. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
34. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?
Hanafy AS; Bassiony MA; Basha MAA
Hepatol Int; 2019 Mar; 13(2):165-172. PubMed ID: 30758786
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Wiegand J; Buggisch P; Mauss S; Boeker KHW; Klinker H; Müller T; Günther R; Serfert Y; Manns MP; Zeuzem S; Berg T; Hinrichsen H; C-Registry GH
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1424-1431. PubMed ID: 31589184
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
Saxena V; Khungar V; Verna EC; Levitsky J; Brown RS; Hassan MA; Sulkowski MS; O'Leary JG; Koraishy F; Galati JS; Kuo AA; Vainorius M; Akushevich L; Nelson DR; Fried MW; Terrault N; Reddy KR
Hepatology; 2017 Oct; 66(4):1090-1101. PubMed ID: 28504842
[TBL] [Abstract][Full Text] [Related]
37. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
[TBL] [Abstract][Full Text] [Related]
39. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.
Asselah T; Bourgeois S; Pianko S; Zeuzem S; Sulkowski M; Foster GR; Han L; McNally J; Osinusi A; Brainard DM; Subramanian GM; Gane EJ; Feld JJ; Mangia A
Liver Int; 2018 Mar; 38(3):443-450. PubMed ID: 28756625
[TBL] [Abstract][Full Text] [Related]
40. Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Liu CH; Chen YS; Wang SS; Liu CJ; Su TH; Yang HC; Hong CM; Chen PJ; Chen DS; Kao JH
Clin Infect Dis; 2018 Jan; 66(2):289-292. PubMed ID: 29020359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
